Extra selling week accelerates growth, but goodwill risks remain
- First quarter fiscal 2027 organic revenue grew 13.7 percent, aided by an extra selling week.
- Cardiovascular revenue surged 20 percent, driven by massive growth in cardiac ablation.
- The company plans to finish separating the Diabetes business by the end of the fiscal year.
- Medical Surgical reported 10 percent growth, though its $19.7 billion goodwill faces impairment risk.
- Finn scores reflect solid performance balanced against average valuation and financial health.
A growth surge meets structural transition
Medtronic started fiscal 2027 with a massive growth beat. First quarter organic revenue jumped 13.7 percent to $9.8 billion, helped by an extra selling week that added approximately $570 million. Cardiovascular led the way with 20 percent growth, fueled by an 88 percent surge in the Cardiac Ablation Solutions business. Medical Surgical also stepped up to 10 percent growth, answering a major concern for investors.
The bull case focuses on this accelerating momentum and a wave of new deals. Medtronic is rolling out new systems and adding partnerships, like the Cornerstone Sentire robotic agreement for international markets. If the company finishes the MiniMed separation by the end of the fiscal year, enterprise margins will mechanically improve and free up capital for more acquisitions.
The bear case centers on execution and accounting. The Medical Surgical segment still carries a thin 12 percent goodwill cushion, meaning any slip in performance could force a material write-down on a $19.7 billion carrying value. The aggressive push into capital equipment and the ongoing inclusion of Diabetes are also creating near-term pressure on gross margins. Finally, fully separating the MiniMed business without unexpected costs remains a key hurdle.
Devices, doctors, and long sales cycles
Medtronic makes money by designing, building, and selling medical devices and related services. Hospitals, health systems, doctors, clinicians, and patients use its products for heart disease, spine and brain conditions, surgery, monitoring, and diabetes care.
The company sells through its own sales teams and independent distributors around the world. This approach matters because many products require doctor training, hospital trust, and support long after the sale. A new device can take time to win use, but a trusted product can stay in use for years.
The business depends heavily on continuous research and development, patents, and strong clinical evidence. It faces risk if a rival launches a better product, if hospitals push prices lower, if procedure volumes slow, or if the company fails to execute its planned divestitures.
What Medtronic sells
Cardiovascular
Reorganized into four divisions covering electrophysiology, interventional cardiology, cardiovascular surgery, and peripheral vascular health. The cardiac ablation business is a massive growth driver.
Neuroscience
These products include spinal implants, neurosurgery tools, and neuromodulation devices. Recent additions include SPR Therapeutics for peripheral nerve stimulation.
Medical Surgical
This includes stapling, vessel sealing, and robotic-assisted surgery systems like Hugo and Sentire. It is a critical segment that needs to maintain growth to protect its goodwill valuation.
Diabetes
This unit includes insulin pumps and continuous glucose monitors. Medtronic plans to separate this business completely by the end of the fiscal year.
Revenue mix and trends
The revenue mix is based on the first quarter of fiscal 2027. Diabetes remains included pending its full separation from the company.
What could go wrong
MiniMed separation stalls
High impact · Medium oddsManagement committed to fully separating the MiniMed business before the fiscal year ends. Delays, unexpected taxes, or separation costs could reduce the value the deal is meant to unlock.
Medical Surgical goodwill write-down
High impact · Medium oddsMedical Surgical carries $19.7 billion of goodwill with only a 12 percent cushion over its carrying value. Weak sales or margin pressure could trigger a massive accounting charge.
Margin pressure from capital equipment
Medium impact · Medium oddsThe aggressive rollout of capital equipment like robotics and mapping systems creates a headwind for gross margins. The new Affera systems and Cornerstone partnership will require heavy initial investments.
In one breath
What does Medtronic do?
Medtronic makes medical devices used in heart care, brain and spine care, surgery, monitoring, and diabetes treatment. It sells to hospitals and patients in more than 150 countries.
Is Medtronic growing fast?
Growth has accelerated recently. First quarter fiscal 2027 organic revenue grew 13.7 percent, driven by strong gains in cardiovascular devices and an extra selling week.
What is Medtronic's biggest risk right now?
The clearest accounting risk is Medical Surgical goodwill. The unit has only a 12 percent cushion over its $19.7 billion carrying value, meaning weaker performance could lead to a material write-down.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 13, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Medical Devices companies
Companies near Medtronic plc in Finn's Medical Devices industry ranking.
